Kornimate/medical-research-clean huggingface dataset:
short effects of a rehabilitation session on gait in patients with cns

Conditions: Spastic Gait; Fall Due to Failure of Support; Fatigue

Summary: the aim of the study is to evaluate the short effects of a two rehabilitation session commonly performed in physical therapy, 1. muscle strengthening of the lower limbs and 2. effort reconditioning with cyclo ergometer, on gait characteristics (kinematics, kinetics and electromyographic) in patients with central nervous system lesion.


Eligibility criteria:
inclusion criteria: * male or female adults aged ≥ 18 years receiving a motor rehabilitation in the service * hemiplegia after stroke or paraplegia incomplete asia c or d or multiple sclerosis (epss \<5). * walking with or without technical assistance * patients who received and signed information and informed consent * patient who received physiotherapy session for rehabilitation of the lower limbs * patients able to perform the entire study exclusion criteria: * patient with safety measure * pregnant women, breastfeeding * patient who has received botulinum toxin injection of in the lower limbs between 3 weeks and 2 months prior to inclusion in the study * bilateral brain damage, cerebellar syndrome, apraxia, severe aphasia * orthopedic complications preventing walking * patients who participated in a clinical study within 3 months prior to inclusion • no affiliation to a social security scheme (beneficiary or assignee)

Keywords: strengthening muscle central nervous system diseases gait
intrathecal magnesium for same-day-surgery

Conditions: Transient Neurologic Syndrome

Summary: 5% hyperbaric lidocaine has lost its usefulness for same-day-surgery (sds) anaesthesia because it has been blamed responsible for the so-called transitory neurological syndrome (tns). this entity appears particularly in patients operated on lithotomy and knee arthroscopy position and obese patients. it is a benign, moderately painful (grade 3-4 out of 10) and self-limited in time, but disturbing enough to be avoided in same-day-surgery cases. other local anesthetics are not competitive with general anesthesia in time to be discharged home from the sds unit. the magnesium ion is well-known for its protective properties on cells with electrical activity. the objective is to confirm that the magnesium ion added as adjuvant to intrathecal (it) lidocaine may antagonize tns incidence. if this hypothesis could be confirmed, the practical and theoretical consequences would be far-reaching. the method to achieve our objective would be a double-blinded randomized clinical trial considering two groups of intrathecal lidocaine: with and without added it magnesium.


Eligibility criteria:
inclusion criteria: * same day surgery patients * operated in lithotomy or arthroscopy position or obese patients exclusion criteria: * american society of anesthesia 3 or 4 patients * younger than 18 or elder than 80 years-old * active lumbar pain * any short of chronic neurologic disease * any short of myopathy * pregnant women * previous history of allergic or toxic reaction to lidocaine, magnesium or fentanyl
a dose-escalation, dose-finding, and expansion study of xl495 in participants with locally advanced or metastatic solid tumors

Conditions: Solid Cancers; Solid Tumor Cancer; Solid Tumor Malignancy; Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer); Metastatic Solid Tumor; Locally Advanced Solid Tumor; Urothelial Cancer of Renal Pelvis

Summary: the goal of this study is to obtain safety, tolerability, pk, and preliminary clinical antitumor activity for xl495 as a single agent and in combination with select cytotoxic agents in participants with locally advanced or metastatic tumors for whom life-prolonging therapies do not exist or available therapies are intolerable/no longer effective.


Eligibility criteria:
inclusion criteria * for all participants * have received at least one standard therapy unless it does not exist, or available therapies are intolerable or no longer effective. * for participants, who qualify for approved molecularly selected therapies such as ras inhibitors, they must have progressed on, relapsed from, been intolerant to, ineligible, or refused those therapies. * expansion stage * diagnosis of metastatic advanced uc (primary tumor: renal pelvis, ureter, urinary bladder, or urethra). * at least one measurable lesion as defined by recist, version 1.1. * participants must be eligible for sacituzumab govitecan treatment as their next line of therapy. * at least one but no more than 3 prior lines of therapy. * eastern cooperative oncology group (ecog) performance status (0-2 for monotherapy; 0-1 for combo) exclusion criteria * prior anticancer treatment, including: * radiation therapy within 2 weeks before first dose of study treatment. * known brain metastases or cranial epidural disease * current or recent severe illness * known history or positive test for human immunodeficiency virus (hiv) unless meets specific criteria. * active infection with hepatitis b virus or hepatitis c virus. * malabsorption syndrome. * history of solid organ, autologous or allogenic stem cell transplant. * diagnosis of another cancer within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with standard therapy. * active autoimmune disease with skin involvement.

Keywords: solid tumor renal tumor metastatic solid tumor urothelial carcinoma
the prognostic value of pgf and sflt1 variations induced by the first low-molecular-weight-heparin injections in women with obstetrical antiphospholipids antibody syndrome starting a new pregnancy and following treatment in accordance with international recommendations

Conditions: Antiphospholipid Syndrome

Summary: the primary objective of this study is to evaluate plasmatic concentrations of free pgf and sflt1 for blood samples taken before a first low-molecular-weight-heparin injection and also for blood samples taken on the 4th day of injections (the latter correspond to the first systematic control of platelet counts) in women who have an obstetric antiphospholipid antibody syndrome and who are initiating a new pregnancy with recommended treatment. our goal is to test the prognostic value of these data on the occurrence of: * pregnancy loss categorized as embryonic loss (before 10 weeks gestation), fetal death (before 20 weeks gestation), stillbirths (from 20 weeks gestation to delivery), and neonatal death defined before reaching 28 days of age. * ischemic placental pathology (pre-eclampsia, retro-placental hematoma, birth of a small-for-gestational-age infant)


Eligibility criteria:
inclusion criteria: * three unexplained consecutive spontaneous abortions before the 10th week of gestation (the recurrent embryo loss subgroup) - or - * one unexplained death of a morphologically normal fetus (fetal loss) at or after the 10th week of gestation (fetal loss subgroup). * women in the aps subgroup: persistently positive for la, and/or acl and/or abeta2gp1 * women initiating a new pregnancy during the 18 month observational period after obstetric aps diagnosis exclusion criteria: * any history of thrombotic events or any treatment given during previous pregnancies that might have modified the natural course of the condition * women whose pregnancy losses could be explained by infectious, metabolic, anatomic or hormonal factors, or associated with paternal or maternal chromosomal causes * seropositivity for hiv, hepatitis b or c * women with antithrombin, protein c, or protein s deficiency, and women with abnormal fibrinogen or with the jak2 v617f mutation were further excluded.
thromboelastography during surgery for malignant pleural mesothelioma

Conditions: Coagulopathy; Mesothelioma

Summary: surgery for malignant pleural mesothelioma is complex and prolonged, and may involve significant blood loss with considerable blood and product transfusion. thromboelastography (teg) is a global assay of coagulation that uses whole blood to produce a tracing that records kinetic changes in clot formation. this study aims provide a better understanding of the coagulation profile of these patients, and will form the basis of a teg-based transfusion algorithm for future surgeries for mesothelioma.

thromboelastography can provide more in-depth and quicker analysis of the complex coagulation processes during surgery

Eligibility criteria:
inclusion criteria: * adult male or female patients undergoing elective surgery for malignant pleural mesothelioma exclusion criteria: * unwilling or unable to provide consent * history of bleeding disorder * on medications that may affect hemostasis
lira-add2sglt2i - liraglutide versus placebo as add-on to sglt2 inhibitors.

Conditions: Diabetes; Diabetes Mellitus, Type 2

Summary: the trial is conducted in asia, europe, north america and south america. the aim of the study is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an sglt2 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes mellitus.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities. trial-related activities are any procedures that are carried out as part of the trial, including activities to determine suitability for the trial. * male or female, age 18 years or older at the time of signing informed consent. * diagnosed with type 2 diabetes mellitus. * hba1c of 7.0-9.5% (53-80 mmol/mol) (both inclusive). * stable dose of an sglt-2 inhibitor as monotherapy or in combination (including fixed-dose drug combination) with a stable dose of metformin (1500 mg or more, or maximum tolerated dose) for at least 90 days prior to the day of screening. all medications in compliance with current local label. * body mass index of 20 kg/m\^2 or above. exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measure as required by local regulation or practice). * history of diabetic ketoacidosis while being treated with sglt2 inhibitors. * renal impairment measured as estimated glomerular filtration rate (egfr) value of less than 60 ml/min/1.73m\^2 as defined by kidney disease improving global outcomes (kdigo) classification using isotope dilution mass spectrometry (idms) for serum creatinine measured at screening. * treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within the past 90 days prior to the day of screening. however, short term insulin treatment for a maximum of 14 days during the 90 days prior to screening is allowed. * family or personal history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. family is defined as a first degree relative. * history or presence of pancreatitis (acute or chronic). * impaired liver function, defined as alt 2.5 or more times upper normal limit at screening. * subjects presently classified as being in new york heart association (nyha) class iv.
intranasal ketamine in treatment-resistant depression

Conditions: Major Depressive Disorder

Summary: the objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (in) ketamine in treatment-resistant depression (trd).


Eligibility criteria:
inclusion criteria: 1. male or female patients, 21-65 years; 2. women of childbearing potential must agree to use a medically accepted means of contraception for the duration of the study; 3. primary diagnosis of major depressive disorder as assessed by the scid-p; 4. current depressive episode; 5. history of a failure to respond to at least one (1) adequate pharmacotherapy trials in the current major depressive episode; 6. subjects must have scored ≥ 30 on the ids-c30 at screening ≥ 24 at treatment day #1 and #2; 7. each subject must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign an informed consent document; 8. subjects must be able to identify a family member, physician, or friend who will participate in the treatment contract and serve as an emergency contact. exclusion criteria: 1. women who plan to become pregnant, are pregnant or are breast-feeding; 2. any unstable medical illness including hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic, neurologic, immunologic, or hematologic disease; 3. clinically significant abnormal findings of laboratory parameters, physical examination, or ecg; 4. lifetime history of schizophrenia, schizoaffective disorder, bipolar disorder, ocd, mental retardation, pervasive developmental disorders, or tourette's syndrome; 5. drug or alcohol abuse or dependence within the preceding 6 months; 6. lifetime abuse or dependence on ketamine or phencyclidine; 7. patients judged by study investigator to be at high risk for suicide. 8. previous participation in a ketamine study at mount sinai

Keywords: ketamine depression treatment resistance intranasal, antidepressant glutamate nmda receptor
profiling based endometrial cancer adjuvant therapy

Conditions: Endometrial Cancer Stage I; Endometrial Cancer Stage II

Summary: this is a prospective, multicenter, randomized phase iii trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.

adjuvant therapy for women with endometrial cancer has increasingly been tailored to prognostic factors to prevent overtreatment and select those women for adjuvant treatment who will have a clinically relevant reduction of the risk of relapse by the adjuvant treatment. risk profiles have traditionally been based on clinicopathological factors such as age, stage, grade, lymph-vascular space invasion (lvsi) and depth of invasion. newer, both molecular-genetic (the cancer genome atlas subgroups) have become available which are strongly related to outcomes and risk of cancer spread. based on 2022 national comprehensive cancer network (nccn) guideline and the ongoing "portec-4a" trial, this randomized trial using integrated genomic-pathologic classification to assign adjuvant treatment for women with stage i-ii high-intermediate and intermediate risk endometrioid adenocarcinoma.

Eligibility criteria:
inclusion criteria: 1. surgery consisting of a total abdominal or laparoscopic hysterectomy, bilateral salpingectomy, pelvic lymphadenectomy or sentinel lymph node mapping and dissection, with or without para-aortic lymphadenectomy, oophorectomy 2. histologically confirmed endometrioid type endometrial carcinoma, international federation of gynecology and obstetrics (figo) 2009 stage i, with one of the following combinations of stage and grade: stage i a, grade 3 stage i b, grade 1 or 2 stage i b, grade 3 stage ii 3. world health organization (who)-performance status 0-2 4. written informed consent exclusion criteria: 1. with residual disease 2. any other stage and type of endometrial carcinoma 3. histological types serous carcinoma or clear cell carcinoma (at least 10% if mixed type), or undifferentiated or neuroendocrine carcinoma 4. uterine sarcoma (including carcinosarcoma) 5. previous malignancy (except for non-melanomatous skin cancer) 6. previous pelvic radiotherapy 7. expected interval between the operation and start of radiotherapy exceeding 8 weeks
project resurgence communication trial

Conditions: Communication Research

Summary: randomized, double-blind, of standard of care vs additional communication and factorial design of intervention letter vs. control letter and ehr vs mail delivery mechanism in patients who canceled visits and did not reschedule over a 90 day period starting march 9, 2020.


Eligibility criteria:
inclusion criteria: * patients with a cancellation or failure to show for a procedure or visit from march 9, 2020 through june 7, 2020 (90 days) and who have not rescheduled as of the date of randomization exclusion criteria: * death
application and translational research of 3d printed in treatment of choledocholithiasis under ercp

Conditions: Common Bile Duct Calculi

Summary: the goal of this clinical trial is to learn about application and translational research of 3d printed models in the surgical treatment of common bile duct stones under endoscopic retrograde cholangiopancreatography. the main question it aims to answer are:compare the differences in stone removal time, surgical complications, and surgical success rate during ercp (+est) surgery between 30 patients who used 3d printing preoperative simulation and 30 patients who did not use it. participating patients will be divided into two groups, one group of 30 patients will use 3d printed models for preoperative simulation planning and then undergo surgery, and the other group will undergo surgery directly without using 3d printed models.


Eligibility criteria:
inclusion criteria: * patients with multiple or single common bile duct stones (total stone diameter ≤1.5 cm) * patients who voluntarily participated in the study and signed the consent form exclusion criteria: * patients with various underlying diseases, such as diabetes, coronary heart disease, and hypertension, that would increase the risk of surgery and affect the outcome of surgery * patients who have had cholangiojejunostomy or roux-en-y anastomosis * combined with intrahepatic bile duct stones require surgical treatment

Keywords: common bile duct calculi ;ercp ;3d printed models
how to provide vascular control of splenic artery aneurysm? report of two cases

Conditions: Arterial Splenic Aneurysm

Summary: spleen artery aneurysm represents the most common visceral aneurysm and the third most common splanchnic aneurysm. most patients have no symptoms and are diagnosed as a part of other diagnostic focuses and examinations. the investigators present two patients with splenic artery aneurysms localized in the splenic hilum, who auspiciously undergo laparoscopic splenectomies with hem-o-lock clips in the vascular hilum without complications. these two cases showed that in addition to the numerous advantages of minimally invasive approaches, there is the possibility to improve laparoscopic technique in terms of safety and economic reasons by using hem - o - lock clips as a hemostatic technique securing the vascular elements of the splenic hilum.


Eligibility criteria:
inclusion criteria: adults patients (\>18 year old) with splenic arterial aneurysms exclusion criteria: patients younger than 18 years old. patients without splenic arterial aneurysms
clinical study on treatment of neurogenic bladder by electroacupuncture on ba liao point under ultrasound guidance

Conditions: To Investigate the Clinical Effect of Acupuncturing Ba Liao for Neurogenic Bladder Under the Guidance of Ultrasound

Summary: to explore acupuncture under the premise of real-time, dynamic and accurate positioning of ba liao point with ultrasound, observe the clinical efficacy of treating neurogenic bladder, clarify the essence of acupoints, and provide a new method for the standardization of acupuncture and moxibustion.


Eligibility criteria:
inclusion criteria: 1. the diagnosis of neurogenic bladder conforms to the main points; 2. symptoms and signs: patients with lower urinary tract dysfunction such as frequency of urination, urgency of urination, inadequacy of urine or retention of urine, urinary incontinence; physical examination showed paresthesia in perineum and saddle area. 3. auxiliary examination; routine urine examination, b - ultrasonography of urinary system and urodynamic examination. 4. indwelling catheter has been removed; 5. conscious and able to accurately express symptoms and signs; 6. patients who inform patients and their families of the research situation in detail and obtain their consent for treatment. - exclusion criteria: 1. lower urinary tract dysfunction caused by non-nervous system factors such as urethral calculi and organic obstruction; 2. patients with serious heart and lung diseases, liver and hematopoietic diseases and mental diseases; 3. patients with prostate cancer, urethral stricture, bladder neck fibrosis, interstitial cystitis, glandular cystitis and other diseases; 4. patients implanted with urethral stents or sacral nerve electrodes; 5. pregnant and lactation women; 6. fear of acupuncture, needle-sickness and blood sickness. -
nd:yag vs alexandrite laser treatment in hidradenitis suppurativa

Conditions: Hidradenitis Suppurativa (HS)

Summary: the purpose of this study is to evaluate whether alexandrite laser treatment is non-inferior to nd:yag (neodymium-doped yttrium aluminum garnet) laser treatment of hidradenitis suppurativa (hs).


Eligibility criteria:
inclusion criteria: * geisinger male or female patients with a diagnosis of hidradenitis suppurativa (all stages of disease) * 12-75 years of age * not on concurrent systemic therapy (e.g., antibiotics, biologic therapies) * must have not used systemic therapies within 2 weeks of enrollment in study * able and willing to provide consent exclusion criteria: * patients who cannot tolerate laser therapy * patients who cannot wear protective eyewear * patients who are pregnant
play as a method to reduce overweight and obesity in children.

Conditions: Childhood Obesity; Sleep Apnea in Obese Children; Studying Maternal and Family Factors That Cause Obesity in Children

Summary: introduction overweight and obesity are characterised by excess fat, which results in weight gain and is identified by the body mass index (bmi). studies show that overweight and obesity are the result of a complex interaction between genetic and environmental factors, which begins prenatally. various studies have shown that physical exercise is an important component of weight loss programmes and that it also benefits the metabolic profile. other authors have reported that greater weight loss is achieved by a programme that includes both diet and exercise, rather than either of these alone. aim the aim of this study is to analyse an intervention based on play as a means of improving the body composition of children with overweight or obesity. design / method the design of the kids-play study is based on cases and controls. the study was conducted in granada (spain) the analysis sample of 98 children was divided into two groups: cases, consisting of 49 children, who participated in an intervention programme based on physical activity, play and nutritional advice (to both the child and the parents); and controls, another 49 children, who received only nutritional advice.


Eligibility criteria:
inclusion criteria: * obese children that want participate in a voluntary way in the research and sign the informed consent. exclusion criteria: * refused to participate * hormonal problems * age \ 12 years * orthopaedic, respiratory * other problems

Keywords: overweight, obesity, play, physical activity, accelerometry.